Estonian health technology company Antegenes has raised €2.3 million in funding.
The investments will help bring personalized cancer prevention into wider use, including in new markets.
In addition to Estonia and the U.K., the company has now started operations in Sweden, Norway, Portugal, and Spain.
In the coming months, it will also enter the German market.
The funding was backed by Enterprise Estonia and the European Institute of Innovation and Technology.
The company also raised €1.6 million in this seed round, led by Pipedrive co-founder Timo Rein, Pipedrive’s first investor Peep Vain and entrepreneurs Aare Kurist and Andreas Henn Otsmaa.
Founded in 2018, the health tech startup aims to develop and implement advanced genetic tests based on polygenic risk scores technology for the precision prevention of major complex diseases.
Antegenes’ novel genetic tests assess a patient’s personal cancer risks and include clinical recommendations for further personalized cancer prevention.
According to the company, tests are based on polygenic risk score technology which helps to clarify an individual’s genetic predispositions to cancer.
This in turn allows for more accurate prevention and early detection measures.
The tests are currently used to determine the genetic risk of four cancers, including breast cancer, prostate cancer, colon cancer, and skin melanoma.
Read more on Tech Gist Africa:
Bemlo raises $3.3 million to solve healthcare labour shortage in Europe
